WB
H M R Hm Mk
Endogenous
530
Rabbit IgG
#Q9NR09
57448
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Hamster, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp147 in human BIRC6 protein.
Background
BIRC6/BRUCE/APOLLON is a member of the inhibitor of apoptosis protein (IAP) family. BIRC6 is a huge 530 kDa membrane-associated protein with a single survivin-like baculoviral IAP repeat (BIR) domain at the amino terminus, and a ubiquitin-conjugating enzyme domain at the carboxy terminus (1-3). Several research studies support the notion that BIRC6 functions as a dual regulator of cell death and cell division (4-6), and BIRC6 is the only essential BIR-containing protein in mammalian cell growth and development (4,7). Research studies have documented the overexpression of BIRC6 in colon cancer stem cells and in other cancer cell lines (8,9). BIRC6 inhibits apoptosis by either 1) binding to and inhibiting caspases (10) or 2) ubiquitinating the IAP antagonist SMAC and the apoptosis initiator caspase 9, thereby targeting these proteins for proteasomal degradation (4,5). BIRC6 itself is regulated by ubiquitination and proteasomal degradation upon stimulation of apoptosis (7,11).
- Hauser, H.P. et al. (1998) J Cell Biol 141, 1415-22.
- Verhagen, A.M. et al. (2001) Genome Biol 2, REVIEWS3009.
- Martin, S.J. (2004) Nat Cell Biol 6, 804-6.
- Hao, Y. et al. (2004) Nat Cell Biol 6, 849-60.
- Qiu, X.B. and Goldberg, A.L. (2005) J Biol Chem 280, 174-82.
- Pohl, C. and Jentsch, S. (2008) Cell 132, 832-45.
- Qiu, X.B. et al. (2004) EMBO J 23, 800-10.
- Van Houdt, W.J. et al. (2011) Mol Cell Proteomics 10, M111.011353.
- Chen, Z. et al. (1999) Biochem Biophys Res Commun 264, 847-54.
- Bartke, T. et al. (2004) Mol Cell 14, 801-11.
- Vaux, D.L. and Silke, J. (2005) Nat Rev Mol Cell Biol 6, 287-97.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
